The Oncology Institute, Inc.
TOI
$4.59
$0.122.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.22% | 41.58% | 36.70% | 21.53% | 10.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.22% | 41.58% | 36.70% | 21.53% | 10.29% |
| Cost of Revenue | 42.42% | 39.19% | 37.54% | 19.58% | 5.39% |
| Gross Profit | 35.17% | 55.54% | 31.70% | 34.35% | 44.11% |
| SG&A Expenses | 11.18% | 12.80% | -5.24% | -3.46% | -10.81% |
| Depreciation & Amortization | -9.42% | -4.39% | 9.54% | 18.91% | 19.81% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.67% | 32.68% | 27.13% | 13.98% | 1.49% |
| Operating Income | 34.29% | 42.10% | 41.86% | 31.49% | 44.85% |
| Income Before Tax | 87.28% | 43.04% | -2.43% | -10.73% | 1.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.28% | 43.04% | -2.43% | -9.88% | 1.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.28% | 43.04% | -2.43% | -9.88% | 1.53% |
| EBIT | 34.29% | 42.10% | 41.86% | 31.49% | 44.85% |
| EBITDA | 39.74% | 48.40% | 48.44% | 36.64% | 50.69% |
| EPS Basic | 90.12% | 55.77% | 19.30% | 11.50% | 4.88% |
| Normalized Basic EPS | 88.26% | 57.91% | 20.63% | 11.00% | 22.49% |
| EPS Diluted | 90.19% | 56.10% | 21.50% | 11.71% | 4.55% |
| Normalized Diluted EPS | 88.26% | 57.91% | 20.63% | 11.00% | 22.49% |
| Average Basic Shares Outstanding | 32.04% | 34.10% | 29.06% | 24.69% | 3.86% |
| Average Diluted Shares Outstanding | 32.04% | 34.10% | 29.06% | 24.69% | 3.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |